Cure Ventures

Co-founder with over 30 years of scientific and therapeutic product leadership in biotech and investment experience at multiple venture capital firms. Led company formation initiatives at 5AM Ventures, serving as interim CEO of Entrada Therapeutics and Chief Scientific Officer roles at Editas, Rhythm, and Agios. Began career at Millennium Pharmaceuticals as first employee.

A senior investment professional with three decades of experience in life sciences and venture capital leadership. Served as Managing Member and President at Omega Funds, sourcing deals and serving on boards of multiple successful biotech companies. Previously founded MVM's US operations and worked in healthcare-focused private equity.

A neuroscience-focused professional with over 30 years of industry experience. Founding scientist and Chief Scientific Officer at Sage Therapeutics, where he built the R&D organization and contributed to discovery and development of two approved drugs and nine additional candidates. Inventor of over 100 patents and author of 200+ scientific publications.

An experienced investment professional with over 10 years of academic licensing and venture investing experience. Spent six years on the investment team at Omega Funds sourcing and leading investments across oncology, immunology, and rare diseases. Previously worked at MIT's Technology Licensing Office managing patent portfolios and license agreements.

Chief Financial Officer overseeing financial and operational functions at the firm and portfolio companies. Brings over 15 years of finance and operations experience supporting both private and capital market funds. Previously at Bain Capital, where he helped launch Life Sciences and Double Impact business units.

A physician and CNS specialist with over two decades of R&D leadership experience in drug discovery and development. Held CEO roles at ABIO-X and Sage Therapeutics, where he led development of industry-leading CNS treatments. Author of over 300 peer-reviewed publications and holder of multiple patents in psychiatry and neuropharmacology.

A seasoned biotech professional with over 30 years of experience translating scientific discoveries into therapies and building early-stage companies. Led teams that discovered six drug candidates currently in clinical development and supported one approved drug. Most recently served as Chief Scientific Officer at Sporos Bioventures.

A drug discovery professional with over 13 years of experience in genetics, genomics, and bioinformatics. Held senior roles at Bristol Myers Squibb, Fog Pharma, Novartis, and Merck, building oncology precision medicine capabilities and leading bioinformatics platforms. Holds PhD in computer science from MIT.

A drug discovery and development expert with over 20 years of experience in program management and scientific leadership across multiple modalities. Brings deep understanding of oncology and metabolic diseases, with experience managing large portfolios of clinical-stage programs at companies including Novartis, AVEO, and Millennium Pharmaceuticals.

An analytical chemist and computer scientist with 25 years spanning technical domains, focusing on accelerating drug discovery and commercialization through advanced algorithms and architecture. Previously co-founded Precision Health Software and served as CTO there, working with biotech startups on machine learning and AI applications for scientific data analysis.

A drug discovery and development professional with over 20 years of experience leading multidisciplinary teams and business development. Holds deep expertise in inflammation, autoimmunity, and oncology, with background spanning multiple modalities including small molecules, biologics, and peptides. Co-founder and CEO of portfolio company Tasca Therapeutics.

Finance professional with nearly two decades of experience across biotechnology, professional sports, and public accounting. Supports firm finance and operational functions with focus on building scalable financial processes in portfolio companies. Recently supported finance and accounting operations at Tortugas Neuroscience and held accounting director roles at Prime Medicine.

An investor or advisor associated with the firm who is listed alongside XenImmune, a portfolio company focused on leveraging immune responses to target tumors.

An investor or advisor associated with the firm who is listed alongside Tasca Therapeutics, a portfolio company working on post-translational modification to expand the druggable proteome.

A researcher with focus on company creation and scientific innovation. Earned his PhD at Johns Hopkins under Nobel Laureate Carol Greider, studying telomere biology and developing diagnostic profiling technology. Previously worked as an associate at Third Rock Ventures, participating in new biotech company formation.

Operations professional with over 30 years of experience in accounting, operations, and administrative roles. Manages calendar, meetings, events, and project coordination for the firm. Previously held finance and operations positions at Easterly Partners Group and worked across diverse industries including construction, travel, and professional fundraising.

A neuroscientist with over a decade of academic and industry research experience in the US and abroad. Conducted doctoral research on neurodegeneration and FTD mechanisms at German research institutes, and worked in clinical operations at Genentech. Transitioning from academic research to biotech venture capital.

A researcher with over 10 years of experience in academic and venture contexts. Conducted molecular and cell biology research at the University of Connecticut focusing on cellular stress responses and cancer biology. Combines scientific expertise with deal sourcing, due diligence, and company creation efforts.

A biomedical researcher with over 10 years of experience in academic research and industry. Earned PhD in cancer biology, focusing on hematopoietic stem cell fate and cancer drug resistance. Recently worked as consultant at ClearView Healthcare Partners and previously interned at ARCH Venture Partners and the University of Chicago's innovation fund.